(a) the publication of this announcement on the Stock Exchange's website does not give rise to any obligation of the Company, its joint sponsors, sponsor-overall coordinator, overall coordinators, advisors or members of the underwriting syndicate to proceed with an offering or a placing in Hong Kong or any other jurisdiction. There is no assurance that the Company will proceed with the offering or the placing; (b) the application to which this announcement relates has not been approved for listing and the S ...

Core Insights - Lifeward Ltd. has appointed Bob Marshall as the new Chairman of the Board, effective January 1, 2026, succeeding Joseph Turk who is transitioning to a new role at Fresenius Medical Care [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3] - The company designs, develops, and commercializes solutions for physical rehabilitation and recovery, with a mission to drive innovation for individuals with disabilities [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [3] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [3] Leadership Changes - Bob Marshall has been a member of Lifeward's Board and Chair of the Audit Committee since 2024, bringing financial leadership and healthcare expertise to the role [2] - Prior to joining Lifeward, Bob Marshall served as Chief Financial Officer and Treasurer of Lantheus Holdings since 2018 and held various positions at Zimmer Biomet Holdings [2]

Core Insights - IBA has acquired ORA, a leader in radiochemistry, enhancing its position in the nuclear medicine sector [1][2] - The acquisition aims to integrate IBA's cyclotron technology with ORA's advanced solutions, providing competitive offerings for hospitals and radiopharmacy networks [3] - This move aligns with IBA's strategic initiatives in nuclear medicine, including partnerships for isotope production and innovation in patient care [4] Financial Aspects - The acquisition is valued between €15-20 million on a cash-free, debt-free basis and is expected to be immediately accretive to IBA's revenue and EBITDA [5] - The transaction will be financed through IBA's own funds and existing credit facilities, with no material impact on IBA's 2025 financial guidance [5] Company Profiles - IBA is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people [7] - ORA Group is recognized for its automated PET radiopharmaceutical synthesizers, contributing to the production of sterile injectable PET drug products [8]

Funding a med-tech company isn’t for VCs who want quick returns.Gabriel Sanchez, co-founder of @enspectra, joins us on Build Mode to talk about how you keep a company afloat when it could be 10 years before your product is able to hit the market.Listen to the full episode here: https://t.co/i6TUbAZCki ...

Core Viewpoint - Resmed will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its commitment to innovative health technologies [1]. Company Overview - Resmed (NYSE: RMD, ASX: RMD) develops health technologies aimed at improving the quality of life for individuals in 140 countries [3]. - The company focuses on AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare [3]. - Resmed envisions a future where individuals can achieve better sleep and breathing through personalized care delivered at home [3]. Event Details - The presentation will be made by Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer [1]. - Access to the live audio-only webcast of the event will be available on Resmed's investor relations website, with a replay accessible for 30 days post-event [2].

Core Insights - Heartflow, Inc. has been recognized for its AI technology in coronary artery disease (CAD) management, with new scientific statements from the American College of Cardiology (ACC) and the American Heart Association (AHA) supporting the prognostic value of coronary plaque quantification [1][3][4] Group 1: Scientific Statements and Recommendations - The ACC's consensus recommendations emphasize the importance of quantitative plaque assessment and the adoption of AI-powered Heartflow Plaque Analysis for personalized cardiac care [1][4] - The AHA statement highlights that plaque burden and composition are critical in managing nonobstructive CAD, indicating that such patients should not be considered low-risk [3][4] - Both ACC and AHA statements advocate for the integration of AI technology in clinical practice to enhance risk stratification and preventive treatment in CAD management [4][5] Group 2: Heartflow's Technology and Validation - Heartflow Plaque Analysis is the only FDA-cleared AI-powered plaque quantification tool, achieving 95% agreement with the gold standard, IVUS [2] - The technology has been validated through extensive clinical evidence, with over 100 studies involving more than 365,000 patients, demonstrating high accuracy and reproducibility [11] - The DECIDE registry indicates that over 50% of patients had their medical management altered when Plaque Analysis was included, compared to management based solely on CCTA [6][11] Group 3: Clinical Integration and Future Directions - Heartflow's technology allows for seamless clinical integration, providing instant quality-reviewed analyses upon order, which facilitates timely clinical decision-making [11] - The company aims to redefine precision cardiovascular care by leveraging its extensive coronary imaging dataset and AI capabilities [8][11] - Heartflow's commitment to rigorous validation and standardization aligns with the ACC and AHA's guidance, positioning the company as a leader in the evolving landscape of CAD management [5][11]

Core Insights - Novanta Inc. is a trusted technology partner for medical and advanced technology equipment manufacturers [1] - The company will have its Chief Operating Officer, Chuck Ravetto, participate in the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on January 14, 2026 [1] Company Overview - Novanta is a leading global supplier of core technology solutions that provide competitive advantages to medical and advanced industrial original equipment manufacturers [2] - The company combines proprietary technology expertise in precision medicine, manufacturing, medical solutions, and robotics and automation to solve complex technical challenges [2] - Novanta engineers core components and sub-systems that deliver extreme precision and performance tailored to customer applications [2] - The growth of Novanta is driven by a team of innovative professionals committed to innovation and customer success [2] - Novanta's common shares are traded on Nasdaq under the ticker symbol "NOVT" [2]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to find those with sustainable growth potential [4] Momentum Score - The Momentum Style Score identifies trends in stock prices and earnings outlooks, helping investors time their positions effectively [5] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with attractive value, strong growth forecasts, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks (4 or 5) should be avoided, even if they have high Style Scores, due to declining earnings forecasts [10] Company Spotlight: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Growth Style Score of B indicating an expected year-over-year earnings growth of 11.2% for the current fiscal year [12] - Recent upward revisions in earnings estimates and a positive earnings surprise average of +2.9% make Stryker a notable option for growth investors [12][13]

Core Thesis - Baxter International Inc. is viewed positively despite recent setbacks, with the stock trading at $19.29 and a forward P/E of 8.12, indicating potential undervaluation [1][2] Company Overview - Baxter operates in essential medtech markets such as IV solutions and infusion pumps, characterized by non-discretionary demand and strong customer relationships [2] - The stock has reached multi-decade lows due to recent challenges, but the selloff is seen as peak capitulation rather than a sign of structural issues [2] Recent Performance - Under new CEO Andrew Hider, Baxter reset expectations in Q3 by cutting guidance, reducing the dividend to save over $300 million annually for deleveraging, and acknowledging slower recoveries in IV fluids and the Novum IQ infusion pump [3] - Reported sales missed lowered expectations, with full-year growth revised to 1-2%, but margins improved, free cash flow turned positive, and operating discipline strengthened [3] Market Position and Outlook - The challenges affecting sentiment are considered temporary and fixable, with the Novum IQ pump previously gaining market share, and IV fluid production fully restored [4] - Demand for capital spending from hospitals remains strong, tariffs are manageable, and deleveraging efforts are on track [4] Strategic Direction - Hider is implementing operational rigor similar to Danaher, positioning Baxter for a self-help story leading into a 2026 investor reset [5] - The stock is trading at approximately 9-10x forward earnings, presenting an asymmetric risk-reward opportunity as temporary issues are mispriced as permanent impairments [5]

Industry Overview - The MedTech sector is navigating a global economy characterized by slowing growth, moderating inflation, and heightened geopolitical uncertainty, impacting healthcare spending and capital allocation decisions [1][2] - Despite challenges such as higher input costs and labor shortages, demand for advanced medical technologies remains steady due to the sector's essential nature and long-term innovation cycle [1][2] Economic Outlook - The IMF forecasts gradual deceleration of global growth through 2026, with advanced economies growing slower than emerging markets, while global inflation is expected to ease unevenly across regions [2] - Slower economic growth may constrain healthcare budgets, but moderating inflation and improved financial conditions could alleviate cost pressures and stabilize procurement trends [2][3] Future Projections - By 2026, the MedTech sector is anticipated to benefit from a more stable macro environment if inflation continues to decline and financing conditions remain favorable [3] - Demand is expected to favor technologies that enhance efficiency, outpatient care, and automation, positioning strong MedTech companies for better performance in a slower-growth economy [3] Investment Considerations - Investors may need to reassess MedTech companies that have seen significant gains but could face challenges in 2026 due to selective hospital spending and increased competition [4][9] - Companies like Globus Medical, TransMedics, and Hims & Hers have experienced strong growth driven by innovation, but sustaining this momentum may be difficult as macro conditions normalize [4][8][9] Company Highlights - **Globus Medical (GMED)**: Reported solid growth in Q3 2025, with a projected EPS and revenue increase of 3.9% and 7.9% respectively for 2026. The stock gained 3.8% over the past year [10][11] - **TransMedics (TMDX)**: Announced strong Q3 2025 results and a strategic collaboration for organ transportation. Expected EPS and revenue growth of 2.4% and 20.4% respectively for 2026. The stock surged 101.4% over the past year [12][14] - **Hims & Hers (HIMS)**: Reported strong Q3 2025 results with growth in subscribers and revenue. Projected EPS and revenue growth of 22.3% and 17.6% respectively for 2026. The stock increased by 32.6% over the past year [15][18]